Technical Analysis for AMPE - Ampio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 0.10 -9.09% -0.01
AMPE closed down 9.09 percent on Monday, July 1, 2024, on 76 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -9.09%
Stochastic Buy Signal Bullish -9.09%
Wide Bands Range Expansion -9.09%
Gapped Up Strength -9.09%

   Recent Intraday Alerts

Alert Time
Rose Above 10 DMA 4 days ago
Up 5% 4 days ago
Up 3% 4 days ago
Up 2% 4 days ago
Up 1% 4 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ampio Pharmaceuticals, Inc. Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Ampion, a non-steroidal anti-inflammatory biologic to treat inflammatory conditions and autoimmune diseases; Optina, an orally administered danazol for the treatment of diabetic macular edema; Vasaloc for the treatment of diabetic nephropathy; and Zertane, an oral drug for treating male sexual dysfunction to premature ejaculation, which is under Phase III clinical trial. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Life Sciences Diabetes Clinical Development Autoimmune Disease Eye Inflammation Healthcare Facilities Kidney Disease Dysfunction Diagnostic Products Diabetic Retinopathy Eye Diseases Macular Edema Diabetic Macular Edema Diabetic Nephropathy Metabolic Disorders Antioxidant Methylphenidate Inflammatory Conditions Inflammation Diseases Male Sexual Dysfunction Sexual Dysfunction

Is AMPE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.298
52 Week Low 0.1
Average Volume 5,506
200-Day Moving Average 1.75
50-Day Moving Average 0.22
20-Day Moving Average 0.15
10-Day Moving Average 0.13
Average True Range 0.06
RSI (14) 32.89
ADX 50.31
+DI 47.34
-DI 10.31
Chandelier Exit (Long, 3 ATRs) 0.24
Chandelier Exit (Short, 3 ATRs) 0.27
Upper Bollinger Bands 0.22
Lower Bollinger Band 0.07
Percent B (%b) 0.17
BandWidth 100.13
MACD Line -0.05
MACD Signal Line -0.06
MACD Histogram 0.0066
Fundamentals Value
Market Cap 113.54 Thousand
Num Shares 1.14 Million
EPS -11.70
Price-to-Earnings (P/E) Ratio -0.01
Price-to-Sales 0.00
Price-to-Book 0.38
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.10
Resistance 3 (R3) 0.10 0.10 0.10
Resistance 2 (R2) 0.10 0.10 0.10 0.10
Resistance 1 (R1) 0.10 0.10 0.10 0.10 0.10
Pivot Point 0.10 0.10 0.10 0.10 0.10
Support 1 (S1) 0.10 0.10 0.10 0.10 0.10
Support 2 (S2) 0.10 0.10 0.10 0.10
Support 3 (S3) 0.10 0.10 0.10
Support 4 (S4) 0.10